Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Inclusion Criteria:

• Participants with histologically or cytologically confirmed advanced or metastaticovarian, CRPC, HR+ HER2- breast, endometrial, colorectal, small-cell lung, orpancreatic cancer, who have progressed following standard-of-care therapy or forwhom there is no standard therapy that confers clinical benefit

• Measurable disease per RECIST v 1.1

• ECOG performance status 0,1 or 2

• Life expectancy of at least 3 months

• Age ≥ 18 years

• Signed, written IRB-approved informed consent form

Exclusion Criteria:

• New York Heart Association Class III or IV cardiac disease, or myocardialinfarction, severe unstable angina, coronary/peripheral artery bypass graft,congestive heart failure within the past 6 months

• Have a corrected QT interval (using Fridericia's correction formula) (QTcF) of >470msec (females) and >450 msec (males)

• Active, uncontrolled bacterial, viral, or fungal infections, requiring systemictherapy

• Active, poorly controlled autoimmune or inflammatory diseases